Wilms' tumor and preferentially expressed antigen of melanoma in patients with myeloid neoplasms treated with azacytidine

Eur J Haematol. 2019 Nov;103(5):527. doi: 10.1111/ejh.13312. Epub 2019 Aug 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antigens, Neoplasm / genetics*
  • Antimetabolites, Antineoplastic / pharmacology
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Azacitidine / pharmacology
  • Azacitidine / therapeutic use*
  • Humans
  • Myeloproliferative Disorders / diagnosis
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / genetics*
  • Myeloproliferative Disorders / mortality
  • Prognosis
  • Treatment Outcome
  • WT1 Proteins / genetics*

Substances

  • Antigens, Neoplasm
  • Antimetabolites, Antineoplastic
  • PRAME protein, human
  • WT1 Proteins
  • WT1 protein, human
  • Azacitidine